Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib

Journal of Clinical Oncology

Volumn 29, Issue 34, 2011, Pages

  De Pas, Tommaso M ^a   Giovannini, Monica ^a   Manzotti, Michela ^a   Trifirò, Giuseppe ^a   Toffalorio, Francesca ^a   Catania, Chiara ^a   Spaggiari, Lorenzo ^a   Labianca, Roberto ^b   Barberis, Massimo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; GEFITINIB; K RAS PROTEIN; SYNAPTOPHYSIN; THYROID TRANSCRIPTION FACTOR 1;

AGED; ARTICLE; BONE ATROPHY; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CASE REPORT; CHROMATIN; CYTOPLASM; DRUG ERUPTION; DRUG RESPONSE; DRUG TOLERABILITY; EPITHELIUM CELL; EXON; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG HILUS LYMPH NODE; LUNG NON SMALL CELL CANCER; LYMPH NODE; MEDIASTINUM LYMPH NODE; MUTATOR GENE; NEUROENDOCRINE TUMOR; NUCLEOLUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SACRUM; SKIN BIOPSY; TREATMENT DURATION;

AGED; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 83255164853     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.2251     Document Type: Article

References (40)

1. Travis WD, Brambilla E, Muller-Hermelink HK, et al. (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France, IARC Press, 2004
2. Travis WD, Linnoila IR, Tsokos MG, et al.: Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma: An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 155:529-553, 1991
3. Cerilli LA, Ritter JH, Mills SE, et al.: Neuroendocrine neoplasms of the lung. Am J Clin Pathol 116:S65-S96, 2001 (suppl 1)
4. Colby TV, Koss MN, Travis WD: Small cell carcinoma and large cell neuroendocrine carcinoma, in Atlas of Tumor Pathology: Tumors of the Lower Respiratory Tract (series 3). Washington, DC, Armed Forces Institute of Pathology, 1995, pp 235-257
5. Rossi G, Cavazza A, Marchioni A, et al.: Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 23:8774-8785, 2005 (Pubitemid 46211523)
6. Iyoda A, Hiroshima K, Moriya Y, et al.: Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg 82:1802-1807, 2006 (Pubitemid 44584914)
7. Rossi G, Marchioni A, Milani M, et al.: TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol 122:884-893, 2004 (Pubitemid 39577356)
8. Yamazaki S, Sekine I, Matsuno Y, et al.: Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer 49:217-223, 2005 (Pubitemid 40966750)
9. Iyoda A, Hiroshima K, Toyozaki T, et al.: Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 91:1992-2000, 2001 (Pubitemid 32476362)
10. Takei H, Asamura H, Maeshima A, et al.: Large cell neuroendocrine carcinoma of the lung: A clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 124:285-292, 2002 (Pubitemid 35025604)
11. Wick MR, Berg LC, Hertz MI: Large cell carcinoma of the lung with neuroendocrine differentiation: A comparison with large cell "undifferentiated" pulmonary tumors. Am J Clin Pathol 97:796-805, 1992
12. Travis WD, Rush W, Flieder DB, et al.: Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22:934-944, 1998 (Pubitemid 28364493)
13. Dresler CM, Ritter JH, Patterson AG, et al.: Clinical-pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 63:180-185, 1997 (Pubitemid 27039058)
14. Jiang SX, Kameya T, Shoji M, et al.: Large cell neuroendocrine carcinoma of the lung: A histologic and immunohistochemical study of 22 cases. Am J Surg Pathol 22:526-537, 1998 (Pubitemid 28213738)
15. García-Yuste M, Matilla JM, Alvarez-Gago T, et al.: Prognostic factors in neuroendocrine lung tumors: A Spanish multicenter study. Ann Thorac Surg 70:258-263, 2000 (Pubitemid 30485759)
16. Jung KJ, Lee KS, Han J, et al.: Large cell neuroendocrine carcinoma of the lung: Clinical, CT, and pathologic findings in 11 patients. J Thorac Imaging 16:156-162, 2001 (Pubitemid 32552216)
17. Mazieres J, Daste G, Molinier L, et al.: Large cell neuroendocrine carcinoma of the lung: Pathological study and clinical outcome of 18 resected cases. Lung Cancer 37:287-292, 2002 (Pubitemid 35286728)
18. Iyoda A, Hiroshima K, Baba M, et al.: Pulmonary large cell carcinomas with neuroendocrine features are high-grade neuroendocrine tumors. Ann Thorac Surg 73:1049-1054, 2002 (Pubitemid 34275875)
19. Hage R, Seldenrijk K, de Bruin P, et al.: Pulmonary large-cell neuroendocrine carcinoma (LCNEC). Eur J Cardiothorac Surg 23:457-460, 2003 (Pubitemid 36411866)
20. Paci M, Cavazza A, Annessi V, et al.: Large cell neuroendocrine carcinoma of the lung: A 10-year clinicopathologic retrospective study. Ann Thorac Surg 77:1163-1167, 2004 (Pubitemid 38452339)
21. Battafarano RJ, Fernandez FG, Ritter J, et al.: Large cell neuroendocrine carcinoma: An aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg 130:166-172, 2005 (Pubitemid 40941686)
22. Zacharias J, Nicholson AG, Ladas GP, et al.: Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: Prognosis after complete resection and systematic nodal dissection. Ann Thorac Surg 75:348-352, 2003 (Pubitemid 36184468)
23. Doddoli C, Barlesi F, Chetaille B, et al.: Large cell neuroendocrine carcinoma of the lung: An aggressive disease potentially treatable with surgery. Ann Thorac Surg 77:1168-1172, 2004 (Pubitemid 38452340)
24. Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
25. Sequist LV, Bell DW, Lynch TJ, et al.: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25:587-595, 2007 (Pubitemid 350002967)
26. Tokumo M, Toyooka S, Kiura K, et al.: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11:1167-1173, 2005 (Pubitemid 40175767)
27. Paez JG, Jänne PA, Lee JC, et al.: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004 (Pubitemid 38720929)
28. Pao W, Miller V, Zakowski M, et al.: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004 (Pubitemid 39209661)
29. Huang SF, Liu HP, Li LH, et al.: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10:8195-8203, 2004
30. Mok TS, Wu YL, Thongprasert S, et al.: Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
31. Lee DH, Han JY, Yu SY, et al.: A randomized phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. Presented at the 13th World Conference on Lung Cancer, San Francisco, CA, July 31-August 4, 2009
32. Mitsudomi T, Morita S, Yatabe Y, et al.: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2010
33. Maemondo M, Inoue A, Kobayashi K, et al.: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010
34. Shiao TH, Chang YL, Yu CJ, et al.: Epidermal growth factor receptor mutations in small cell lung cancer: A brief report. J Thorac Oncol 6:195-198, 2011
35. Fukui T, Tsuta K, Furuta K, et al.: Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci 98:1714-1719, 2007 (Pubitemid 47487906)
36. Zakowski MF, Ladanyi M, Kris MG: EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 355:213-215, 2006 (Pubitemid 44050422)
37. Okamoto I, Araki J, Suto R, et al.: EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol 17:1028-1029, 2006 (Pubitemid 43779001)
38. Tatematsu A, Shimizu J, Murakami Y, et al.: Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 14:6092-6096, 2008
39. Araki J, Okamoto I, Suto R, et al.: Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer. Lung Cancer 48:141-144, 2005 (Pubitemid 40381011)
40. Morinaga R, Okamoto I, Furuta K, et al.: Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 58:411-413, 2007 (Pubitemid 350051499)